Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples-Reference-Cited by-同舟云学术

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples

Published:2019-06-20 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Vivancos Ana,Aranda Enrique,Benavides Manuel,Élez Elena,Gómez-España Maria Auxiliadora,Toledano Marta,Alvarez Martina,Parrado Maria Rosario Chica,García-Barberán Vanesa,Diaz-Rubio Eduardo

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-45616-y.pdf

Reference34 articles.

1. Allegra, C. J., Rumble, R. B. & Schilsky, R. L. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract 12, 180–181, https://doi.org/10.1200/jop.2015.007898 (2016).

2. Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27, 1386–1422, https://doi.org/10.1093/annonc/mdw235 (2016).

3. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626–1634, https://doi.org/10.1200/jco.2007.14.7116 (2008).

4. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359, 1757–1765, https://doi.org/10.1056/NEJMoa0804385 (2008).

5. Douillard, J.-Y. et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. New Engl J Med 369, 1023–1034, https://doi.org/10.1056/NEJMoa1305275 (2013).

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value;Disease Markers;2024-02-13

2. Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients – a single-institution experience utilising circulating tumour DNA;Współczesna Onkologia;2024

3. Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR;International Journal of Molecular Sciences;2023-10-27

4. Rapid Idylla mutational testing to detect EGFR mutations in plasma samples and to monitor therapy in advanced non-small cell lung cancer patients;Pathology;2023-08

5. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials;Cancers;2023-04-01